Press Releases
September 17, 2025
Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
September 11, 2025
Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
September 10, 2025
Media Update: ECTRIMS: Sanofi showcases patient focus across multiple sclerosis
Upcoming Events
Past Events
31Jul
2025
Second Quarter 2025
Second quarter 2025 results were reviewed by management during a live audio webcast with the financial community on July 31, 2025. The presentation was followed by a Q&A session.
Quarterly results
24Apr
2025
First quarter 2025
First quarter 2025 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.
Quarterly results
30Jan
2025
Fourth Quarter & Full Year 2024 Results
Fourth quarter and full year 2024 results were reviewed by management during a live audio webcast with the financial community on January 30, 2025. The presentation was followed by a Q&A session.
15:00 - 16:30 CET (9:00am – 10:30am EST)
Quarterly results